| Dr Trevor Thomas Green, DO | |
|
2810 N Swan Rd 100, Tucson, AZ 85712-6300 | |
| (520) 324-2030 | |
| (520) 445-6049 |
| Full Name | Dr Trevor Thomas Green |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 19 Years |
| Location | 2810 N Swan Rd 100, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770796716 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 2006-01417 (North Carolina) | Secondary |
| 207L00000X | Anesthesiology | 006090 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Medical Center | Tucson, AZ | Hospital |
| Banner - University Medical Center Tucson Campus | Tucson, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valley Anesthesiology Consultants Inc | 4880591841 | 371 |
| Anesthesia Services Of Arizona Pc | 6608247374 | 58 |
| Banner -- University Medical Group | 7719899871 | 819 |
News Archive
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
Oklahoma has opted not to proceed with a state-based exchange or with the Medicaid expansion, while Republican governors from Tennessee, Utah and Iowa continue to press the Department of Health and Human Services for more guidance.
Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.
› Verified 6 days ago
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
Oklahoma has opted not to proceed with a state-based exchange or with the Medicaid expansion, while Republican governors from Tennessee, Utah and Iowa continue to press the Department of Health and Human Services for more guidance.
Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.
› Verified 6 days ago
| Entity Name | Valley Anesthesiology Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285660704 PECOS PAC ID: 4880591841 Enrollment ID: O20031217000620 |
News Archive
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
Oklahoma has opted not to proceed with a state-based exchange or with the Medicaid expansion, while Republican governors from Tennessee, Utah and Iowa continue to press the Department of Health and Human Services for more guidance.
Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.
› Verified 6 days ago
| Entity Name | Old Pueblo Anesthesia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194770768 PECOS PAC ID: 6406842723 Enrollment ID: O20040422000657 |
News Archive
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
Oklahoma has opted not to proceed with a state-based exchange or with the Medicaid expansion, while Republican governors from Tennessee, Utah and Iowa continue to press the Department of Health and Human Services for more guidance.
Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.
› Verified 6 days ago
| Entity Name | Anesthesia Services Of Arizona Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336857085 PECOS PAC ID: 6608247374 Enrollment ID: O20230118000286 |
News Archive
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
Oklahoma has opted not to proceed with a state-based exchange or with the Medicaid expansion, while Republican governors from Tennessee, Utah and Iowa continue to press the Department of Health and Human Services for more guidance.
Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Trevor Thomas Green, DO 2810 N Swan Rd 100, Tucson, AZ 85712-6300 Ph: (520) 324-2030 | Dr Trevor Thomas Green, DO 2810 N Swan Rd 100, Tucson, AZ 85712-6300 Ph: (520) 324-2030 |
News Archive
Scientists have identified a quantitative method to measure changes in biomarkers, which may reduce or eliminate the need for invasive biopsies. The method, described in the February 2016 issue of The FASEB Journal uses a novel chimera design of DNA and small DNA with a companion contrast agent to allow antibodies to cross cellular membranes.
After years of research, development and testing, a new class of drugs is emerging on the market with two frontrunners acting as harbingers of what's to come. The cover story in Chemical & Engineering News, ACS' weekly newsmagazine, explores the potential of these antibody-drug conjugates (ADCs) and the challenges in developing and manufacturing them.
Oklahoma has opted not to proceed with a state-based exchange or with the Medicaid expansion, while Republican governors from Tennessee, Utah and Iowa continue to press the Department of Health and Human Services for more guidance.
Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors and the poor prognosis for patients whose cancer recurs.
› Verified 6 days ago
Holly Jeanne Graham, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5301 E Grant Rd, Thmep, Tucson, AZ 85712 Phone: 520-324-5095 | |
Dr. Ryan William Matika, MD Anesthesiology Medicare: May Accept Medicare Assignments Practice Location: Department Of Anesthesiology, 1501 N. Campbell Avenue, Tucson, AZ 85724 Phone: 520-626-7221 | |
Kevin Evans, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2810 N Swan Rd Ste 100, Tucson, AZ 85712 Phone: 520-324-2030 Fax: 520-445-6019 | |
Dr. Rhesa Screven Farmer Iii, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3390 N Campbell Ave, Ste 110, Tucson, AZ 85719 Phone: 520-795-7650 Fax: 520-325-1622 | |
Stuart Hameroff, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1501 N Campbell Ave, Tucson, AZ 85724 Phone: 520-694-8888 Fax: 520-626-6066 | |
Dr. David Bruce Longenecker, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3390 N Campbell Ave, Suite 110, Tucson, AZ 85719 Phone: 520-795-7650 | |
Dr. Murray Manson, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6213 N Pascola Circle, Tucson, AZ 85718 Phone: 520-529-1830 Fax: 520-529-7314 |